字幕列表 影片播放 列印英文字幕 Unknown: There are roughly 6 million people living with Alzheimer's in the U.S.; a figure that is expected to more 3 than double by 2050. The memory-robbing disease kills more than 120,000 Americans a year, making it the sixth leading cause of death. Alzheimer's disease is a devastating disease of progressive dementia, where people can lose various aspects of their cognitive functioning, their ability to remember key things and people. Genius not aware of the fact that she can ask me the same question 10 times 10 minutes, oh maybe nine and a half. The US has spent billions on research but still hasn't been able to develop a drug that targets the cause of the disease. We know that it's a costly disease and the burden of that cost continues to grow exponentially. A drug for any company that could treat Alzheimer's successfully would be seen as just a goldmine for Wall Street and the huge gift to society. Now one biotech company thinks it's cracked Alzheimer's tricky code and a drug known as aducanemab now sold as Aduhelm. This is an approval for Biogen This is a huge stock event to 50% pop on this FDA approval. But Biden's reported only a fraction of estimated sales, the company's share price has nearly halved. Major insurers haven't decided whether to cover the treatment, which Biogen originally priced at roughly $56,000 per year. But now the company is bringing that down by about 50% to hopefully boost sales. In all this comes as the FDA itself phases investigations into its edge home decision, which went against the advice of its own advisors. There's been a real mixed reception among doctors because of the lack of completely convincing data supporting whether the drug works. So the question is who will be prescribing this? Who will be monitoring it? Who will have access to it and who's going to pay for it? The US spends roughly $3 billion on Alzheimer's and dementia research every year. That's up 360%. Over the past five years, spending on people with Alzheimer's is said to cost Medicare $599 billion by 2050. The fact is, is that Alzheimer's is not just a disease of the individual who has it. It is a burden on also individuals who are caregivers as well. In 2020, there are over 11 million Americans who are providing unpaid care for individuals with Alzheimer's, that unpaid care is costly to them and to their family. I'm Eugenia Zukerman, and I have Alzheimers I'm Dick Novik retired from the broadcasting business to be able to take care of my wife. Once I heard she was diagnosed with Alzheimer's. Eugenia was diagnosed three years ago, every senior walked around the house with the glasses on their foreheads and wear my glasses. But this got beyond that this got to you know, it constantly asked me the same question a certain amount of disorientation. My daughters were saying to me Mom, something is wrong with you. You're not sounding okay. We have to take you to the hospital and get you tested. I said no way. But of course, I ended up being taken to the hospital and being looked at very carefully. One of the biggest shocks to us was if you go to any other specialist, gastroenterologist and they give you a medicine for your stomachache. with Alzheimer's, there has been really no commonly prescribed medication. Alzheimer's is a notoriously difficult disease to treat. But there are a couple drugs available there, you know, at this point many decades old, and they can help with some of the symptoms associated with Alzheimer's disease, but in general, they don't work very well. So there hadn't been a new Alzheimer's drug that proved in almost two decades when ad you helm came along, and nothing out there to try to actually affect the underlying drivers of the disease. That's where Biogen comes in. In recent years, his portfolio of other drugs has faced growing generic competition. In 2020, the company posted $13.4 billion in revenue, and near six and a half percent drop year over year, researchers designed Agia home to target one of the diseases defining characteristics. What happens with an Alzheimer's disease is that there's a faulty cleavage of amyloid in a sense that it results in the production of these insoluble and sticky amyloid beta we call them and when this forms, what happens is that that accumulate in the brain and around it, surrounding it are signs of inflammation, oxidation and brain cell death. So Lily has a very similar drug to Biogen is called Diana Mab, which it has been developing and had some really promising earlier stage results that showed not just that it clears the amyloid plaques from the brain but also that there is an effect on cognition. But the path to an FDA approved Alzheimer's drug has been riddled with failures. Over 200 potential medicines failed their trials over the past decade, and in early 2019 Aduhelm almost became one of them.